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Abstract 
Background: As part of the effort to develop an enterotoxigenic Escherichia coli (ETEC) human challenge model for 
testing new heat-stable toxin (ST)-based vaccine candidates, a controlled human infection model study based on the 
ST-producing ETEC strain TW11681 was undertaken. Here, we estimate stool TW11681 DNA concentration and evalu-
ate its association with dose, clinical symptoms, and with levels of antibodies targeting the CfaB subunit of the ETEC 
Colonization Factor Antigen I and the E. coli mucinase YghJ. Nine volunteers ingested different doses of the strain and 
were subsequently followed for 9 days with daily stool specimen collection and clinical examination. Stool DNA was 
purified by using a newly developed microplate-based method, and DNA originating from TW11681 was quantified 
by using a probe-based quantitative PCR assay. Antibody levels against CfaB and YghJ were measured in serum col-
lected before and 10 and 28 days after TW11681 was ingested by using a bead-based flow cytometry immunoassay.
Results: For 6 of the 9 volunteers, the stool TW11681 DNA concentration increased sharply a median 3.5 (range 
2–5) days after dose ingestion, peaking at a median of 5.4% (range 3.3–8.2%) of the total DNA in the specimen. The 
concentration then fell sharply during the subsequent days, sometimes even before the onset of antibiotic treatment. 
The size or timing of these proliferation peaks did not seem to be associated with the number of TW11681 bacteria 
ingested, but the 2 volunteers who developed diarrhea and all five who experienced abdominal pains or cramps had 
these peaks. The 3 volunteers who did not have the proliferation peaks experienced fewer symptoms and they gener-
ally had relatively low CfaB- and YghJ-specific antibody levels before ingesting the strain and subsequently weaker 
responses than the other volunteers afterwards.
Conclusions: Since the lack of proliferation peaks appears to be associated with fewer clinical symptoms and lower 
serum antibody responses to virulence factors of the infecting strain, it may be important to account for proliferation 
peaks when explaining results from controlled human infection model studies and for improving the accuracy of 
protective efficacy estimates when testing new ETEC diarrhea vaccine candidates.
Keywords: Human volunteers, Experimental infection, Diarrhea, Enterotoxigenic Escherichia coli, Heat-stable 
enterotoxin, Controlled human infection model, Feces, Flow cytometry, Real-time polymerase chain reaction, 
Genomic DNA purification
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Gut Pathogens
*Correspondence:  hans.steinsland@uib.no 
5 Centre for International Health, Department of Global Public Health 
and Primary Care, University of Bergen, Bergen, Norway
Full list of author information is available at the end of the article
Page 2 of 8Vedøy et al. Gut Pathog  (2018) 10:46 
Background
Infections with enterotoxigenic Escherichia coli (ETEC) 
are a common cause of childhood diarrhea in low- and 
middle-income countries (LMICs) [1], as well as of diar-
rhea among travelers to these countries [2]. ETEC has 
emerged multiple times from the E. coli population 
through acquisition of plasmid genes encoding the large 
and highly immunogenic heat-labile toxin (LT) and/or 
the small and non-immunogenic heat-stable toxin (ST) 
[3, 4]. ETEC colonizes parts of the small intestine where 
it attaches itself to the intestinal wall cell surface, and 
most ETEC also produce colonization factors, which are 
surface appendages that help to stabilize the attachment 
[5]. Secreted ST binds to the guanylate cyclase-C recep-
tor on the epithelial cell surface, which leads to increased 
secretion of salts into the intestinal lumen, which again 
drives diarrheal symptoms [6].
ETEC that produce ST, either alone or in combination 
with LT, are among the most important contributors to 
moderate and severe diarrhea among LMIC children, in 
addition to rotavirus, Cryptosporidium and Shigella [1]. 
Symptomatic infections with ST-producing ETEC also 
appear to be associated with an increased case fatality 
risk [1]. Efforts to develop effective ETEC vaccines are 
mainly focused on inducing anti-colonizing immunity 
through immunization with the main ETEC coloniza-
tion factor antigens [7]. So far no effective vaccines have 
been produced, but several vaccine candidates are under 
development [8]. More recently, efforts have also been 
made to develop vaccines based on ST itself [8, 9].
Human ETEC may produce one of two close to iden-
tical variants of ST called porcine ST (STp) and human 
ST (STh). The ST-based vaccine development effort is 
primarily focused on STh since STh-producing ETEC are 
arguably a substantially more important cause of diar-
rhea among young LMIC children [10, 11].
To test the efficacy of ST-based vaccines, there is a 
need to develop a vaccine challenge model that allows 
for measuring the vaccines’ protection against diarrhea 
when volunteers are experimentally infected with strains 
that only produce ST. While controlled human infection 
models based on strains producing both ST and LT are 
available [12, 13], these strains may not be useful in vac-
cine challenge models for testing ST-based vaccines since 
the activity of LT could mask the effects of otherwise pro-
tective anti-ST immune responses. As part of the process 
to evaluate whether ETEC strain TW11681 could be suit-
able for use in a vaccine challenge model, we monitored 
the changes in TW11681 concentration in the stools of 
9 volunteers experimentally infected with this strain and 
investigated whether changes in concentration were asso-
ciated with differences in clinical symptoms and immune 
responses.
Results
Nine volunteers were followed for 9  days starting from 
the time of ingesting 1 × 106, 1 × 107 or 1 × 108 colony-
forming units (CFUs) of TW11681, and stool samples 
were successfully collected from 72 of these 81 volunteer-
days (Fig. 1). Stool samples were not obtained on 4 vol-
unteer-days (2 volunteers) because no stools were passed, 
while we failed to collect samples from passed stools on 
5 volunteer-days (5 volunteers). Two of the 9 volunteers 
developed diarrhea, both of which were mild episodes, 
while five experienced mild or moderate abdominal pain 
or cramps (Fig. 1). Other observed signs and symptoms 
were few and mild. All volunteers started ciprofloxacin 
treatment 5 days after ingesting the dose.
Each volunteer cumulatively passed a median 1421  g 
(Interquartile range 1117 g, 1812 g; Range 780 g, 2114 g) 
of stools during the 9  day period, and all passed stools 
were grade 1 and 2 (formed), except for the stools passed 
during the two diarrheal episodes, which were grade 3 
(viscous opaque liquid or semiliquid). ETEC was micro-
biologically detected in daily passed stool specimens for 
up to a median of 6 (range: 3–8) days after ingesting the 
dose (Fig. 1). The microbiological analyses yielded ETEC-
negative results on 16 of the 81 volunteer-days, and stools 
from 13 of these days were found positive for TW11681 
DNA in at least one qPCR replicate, albeit usually at a low 
percentage; the median of the mean of the TW11681-
positive reactions was 0.006% (range: 0.001%–0.550%). 
Since the microbiological analyses detect mainly viable 
ETEC, some of the TW11681 DNA detected by qPCR 
may have originated from non-viable cells.
qPCR assay validation
In the stool specimens collected on the day of infection, 
the O19 polymerase gene could either not be detected 
in the qPCR assay or was present in small amounts. This 
suggests that the volunteers were not extensively colo-
nized with other O19 E. coli strains prior to ingesting 
the dose, and that most of the qPCR signals we observe 
can therefore be attributed to TW11681. The standard 
curve based on the positive control dilution series had 
acceptable curve fitting parameters (97% PCR efficiency 
and a mean squared error of 0.01), the assay has a linear 
dynamic range for detecting between 13 and 132,000 
TW11681 genomes, and none of the no-template con-
trols showed signs of amplification.
We found no indication that any of the qPCR results 
were affected by PCR inhibitors in the template DNA. 
Of the sample reactions that were based on the 0.1  ng/
µl template DNA, 84, representing 43 different sam-
ples, gave results that fell within the dynamic range of 
the assay. The median within-sample quantitation cycle 
(Cq) difference between reactions based on 0.1 ng/µl and 
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1.0  ng/µl template DNA for these 43 samples was 3.10, 
the differences looked normally distributed (Shapiro–
Wilk Normality Test p value: 0.22; skewness coefficient 
− 0.51), and there were no clear outliers. If the ETEC 
quantitation estimates presented here were substantially 
biased by PCR inhibitors from the template DNA prepa-
rations, the differences in Cq estimates between the two 
template concentrations would probably be substantially 
more skewed towards no Cq difference.
TW11681 proliferation and association to clinical 
symptoms
For each stool specimen, we isolated DNA and quanti-
fied the number of TW11681 genomes by qPCR. The 
estimated TW11681 concentration in a stool specimen 
is represented by percent estimated weight of TW11681 
genome DNA relative to the weight of all DNA from 
the specimen. The main weight of other DNA in the 
stool specimen probably originates from the remaining 
gut microbiota and from epithelial cells that has been 
exfoliated from the large intestine [14]. Assuming the 
production of these other cell populations remains rela-
tively stable during the follow-up period, the changes 
in TW11681 DNA concentration should reflect actual 
changes in stool TW11681 proliferation during the 
infection.
As seen in Fig.  1, there were two main patterns for 
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Fig. 1 Percent DNA from TW11681 in stools from experimentally infected human volunteers. Four replicates, two of which were based on tenfold 
diluted template DNA, were performed on DNA isolated from one stool specimen from each day from each volunteer. Results are presented as the 
weight percentage of the DNA isolated from the specimen that originated from TW11681. Open (○) or closed (●) circles at the bottom of each 
graph indicate that no stools were passed, or that passed stools were not analyzed, respectively, on the given day. Crosses (×) or plusses (+) show 
the estimated TW11681 DNA percentages for individual qPCR runs where the results fell inside or outside the linear dynamic range of the assay, 
respectively. Results from all replicates are plotted, but some individual points may not be discernible due to overlap. The line-graphs represent the 
average percentage of all four replicates. The gray horizontal bars indicate which days the volunteers had ETEC microbiologically detected in their 
stool samples (“ETEC+”), were receiving ciprofloxacin treatment (“Cipro”), had abdominal pains or cramps (“Abd.”), or had diarrhea (“Dia.”)
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Six volunteers (EV10, EV11, EV13, EV16, EV17, and 
EV18) had a rapid and substantial increase and subse-
quent decline in TW11681 DNA concentration, with 
mean maximum concentration at 5.3% (range 3.3–8.2%) 
a median 3.5 (range 2–5) days after dose ingestion. The 
remaining 3 volunteers (EV12, EV14, and EV15) had low 
TW11681 DNA concentrations (< 0.5%) throughout the 
follow up period. The size of the TW11681 proliferation 
peaks did not seem to increase with inoculum size. Both 
volunteers who developed diarrhea and all five who expe-
rienced abdominal pain or cramps had these peaks, but 
the peaks did not necessarily coincide with the onset of 
symptoms. For example, EV11’s diarrheal episode and 
EV13’s episode with abdominal pain or cramps was over 
even before the TW11681 DNA concentration peaked. 
Notably, for EV10, EV16, and EV18, the rapid decline in 
the TW11681 DNA concentration started before onset of 
the antibiotic treatment.
Immune responses
All volunteers except EV14 seemed to develop some 
serum antibody responses to the CfaB subunit of the 
ETEC Colonization Factor Antigen I (CFA/I) and the E. 
coli mucinase YghJ (Fig. 2). The three volunteers who did 
not have the TW11681 proliferation peaks (EV12, EV14, 
and EV15) had low levels of pre-existing CfaB- and YghJ-
specific serum antibodies, similar to most of the other 
volunteers, but tended to have lower increases in antibody 
levels to these proteins than the other volunteers. Of the 6 
volunteers who had TW11681 proliferation peaks, EV13 
had the smallest peak as well as the lowest CfaB- and 
YghJ-specific serum antibody level increases (Fig. 2).
Discussion
We found that the volunteers who were experimentally 
infected with ETEC strain TW11681 either had or had 
not a sharp and substantial increase in stool TW11681 
excretion during follow-up, and that the substantially 
increased excretion sometimes dropped even before 
onset of the antibiotic treatment. The lack of these prolif-
eration peaks tended to correlate with fewer clinical signs 
and symptoms, as well as lower increases in TW11681 
virulence factor-specific serum antibody levels. These 
findings are relevant for the efforts to understand the 
dynamics of human ETEC infections, as well as for inter-
preting results from controlled human infection model 
studies and vaccine challenge trials.
Proliferation peaks similar to those observed in the 
current study has previously been observed by Pop 
et  al. [15]. They performed 16S rRNA gene sequenc-
ing on DNA from daily collected stools specimens from 
12 volunteers experimentally infected with ETEC strain 
H10407 and estimated the proportion of all bacteria 
in the stool specimen that was E. coli. In that study, all 
7 volunteers who developed diarrhea had E. coli prolif-
eration peaks, and all seven peaks were larger than those 
seen in the present study, with E. coli representing up to 
78% of the bacterial population. In contrast to the present 
study where the proliferation peaks were found in both 
volunteers with and without diarrhea, E. coli proliferation 
peaks were not seen among the 5 volunteers who did not 
develop diarrhea.
The large difference in proliferation peak sizes between 
these two studies could, of course, be a result of differ-
ences in methods to estimate the strain concentra-
tions, but it could also be attributed to whether or not 
the specimens were collected during diarrheal episodes 
and the severity of these episodes. In the present study, 
experimental infection with TW11681 only resulted in 
two mild diarrheal episodes during which the stool con-
sistency only briefly reached grade 3 (viscous opaque 
liquid or semiliquid). Infections with H10407 tend to 
give longer and more severe episodes of grade 4 and 5 
(watery) stools [12], and we expect the larger prolifera-
tion peaks they observed are mainly a result of the diar-
rhea purging the colon of other bacteria, leaving the 
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Fig. 2 Maximum changes in CfaB- and YghJ-specific serum IgA and 
IgG/IgM responses. The numbers represent each volunteer’s study 
ID number (e.g. “10” = “EV10”). Open circles (○) represent the three 
volunteers who did not have TW11681 proliferation peaks in their 
stools, while closed circles (●) represent the six who did. The Y-axis 
values are plotted logarithmically and represent the maximum values 
of the median fluorescence intensity (MFI) of assay results based 
on serum collected 10 and 28 days after infection, minus the MFI of 
assay results based on the serum collected before the volunteer had 
ingested the dose. Prior to this calculation, MFI of assays results based 
on the negative controls were subtracted from all values
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that have been secreted from the small intestine. This 
explanation is supported by results from a study by Lind-
say et  al. where qPCR quantitation was used to investi-
gate the correlation between stool ETEC quantities and 
having diarrhea. They found a higher concentration of 
ETEC in diarrheal than in non-diarrheal specimens that 
had been collected from the same volunteer on the same 
day [16].
Including qPCR results from watery diarrhea speci-
mens in studies like these will probably complicate direct 
comparison of results, but the variation in peak size may 
turn out to be biologically less important than the actual 
presence of these peaks. In the current study, for exam-
ple, peak presence, but not peak size, tended to be cor-
related with more symptoms and higher levels of serum 
antibody responses to the TW11681 virulence factors. 
The observation that symptoms tended to precede the 
stool proliferation peaks could indicate that the increased 
production of TW11681 that probably occurs in the 
small intestine is responsible for the symptoms, but that 
it takes time for the cells to pass through the colon.
Since a lack of a proliferation peak appears to be cor-
related with fewer symptoms, it may be advisable to per-
form strain proliferation monitoring of the volunteers 
when testing the efficacy of new vaccines against ETEC 
diarrhea. If a vaccinated volunteer does not develop a 
proliferation peak after being infected with the challenge 
strain, any lack of diarrhea may be a consequence of sub-
optimal colonization rather than be attributable to pro-
tection by the vaccine candidate.
Finally, we developed a new microplate-based DNA 
purification method for this project in order to obtain 
consistently clean DNA from a large number of stool 
specimens without having to work with individual tubes. 
Although both manual and automated microplate-based 
DNA purification methods and kits already exist, we 
find that these tend to be less effective at isolating DNA 
from Gram-positive than from Gram-negative bacteria in 
stools and that the purity of the DNA often varies. For 
the presented method, DNA is released from cells in the 
stools through treatment with heat, soaps, enzymes, and 
mechanical shearing, and subsequently purified by first 
salting-out proteins and soaps, precipitating with salts 
and alcohol, and crowding onto magnetic beads before a 
final rinse. We believe the combination of the three puri-
fication steps ensures that the purified stool DNA will be 
consistently sufficiently clean for use in PCR assays.
Conclusions
We found that human volunteers experimentally infected 
with ETEC strain TW11681 either had a substantial and 
often self-limiting increase or no clear increase in stool 
TW11681 excretion during the days following ingestion 
of the bacteria, and that the presence of proliferation 
peaks appeared to correlate with more clinical symp-
toms and higher serum antibody response levels against 
TW11681 virulence factors. Further studies are needed 
to identify the underlying reasons for the lack of these 
proliferation peaks and if and how they relate to coloni-
zation and subsequent symptoms and immune response 
development. However, our results underline the need 
to monitor stool ETEC concentration during controlled 
human infection model studies to better explain vari-
ation in responses to the infection, and during human 
challenge vaccine trials to increase the accuracy of the 
protective efficacy estimates when testing new vaccine 
candidates against ETEC diarrhea.
Methods
Strain description
ETEC strain TW11681 (O19:H45; GenBank BioProject: 
PRJNA59749) was isolated in Guinea-Bissau in 1997 
from the stool of a 6  month old girl who had diarrhea 
[10]. This ciprofloxacin-sensitive strain has genes encod-
ing the STh and the two colonization factors CFA/I and 
Coli Surface antigen 21 (CS21). TW11681’s genome size 
is approximately 5.30 Mbp, around 316 kbp of which is 
plasmid DNA [17]. Phylogenetically, it belongs to an 
epidemiologically important ETEC lineage that is often 
found to be associated with childhood diarrhea (ETEC8 
family [3] and Lineage L6 [4]).
Controlled human infection model study
The volunteer study is based on experimental infection 
of nine healthy 23–28  years old students (1 man and 8 
women) living in Norway who had not traveled to LMICs 
within 12 months prior to study start. In brief, the volun-
teers were included in the study in successive groups of 
three during the fall of 2016. The volunteers had fasted 
overnight before orally ingesting the dose at 11:00 a.m. 
at the Infectious Diseases Ward at Haukeland Univer-
sity Hospital, Bergen, Norway. They drank 120 ml 1.33% 
bicarbonate buffer, followed after 1 min by 30 ml of the 
bicarbonate buffer containing 1 × 106, 1 × 107, or 1 × 108 
CFUs of TW11681. The volunteers were allowed to drink 
and eat normally 1  h after that. The TW11681 doses 
were prepared by culturing the strain on animal product-
free LB agar plates before harvesting, and the cells were 
re-suspended and subsequently washed three times in 
phosphate-buffered saline before being administered 
to the volunteers. Clinical signs and symptoms were 
self-reported by the volunteers during the daily clini-
cal evaluations, stool samples were obtained daily, and 
blood samples were collected on the day of the infection 
and 7, 10, and 28 days after. Stool consistency was graded 
on a scale from 1 to 5, where the grades seen in this 
Page 6 of 8Vedøy et al. Gut Pathog  (2018) 10:46 
study were 1 and 2 (firm and soft formed stools, respec-
tively) and 3 (viscous opaque liquid or semiliquid which 
assumes the shape of the container). The volunteers were 
considered to have diarrhea if they pass grade ≥ 3 stools 
with a combined weight of ≥ 200  g over a 48-h period 
or a single grade ≥ 3 stool of ≥ 300 g. To clear the infec-
tion, ciprofloxacin treatment (500  mg orally two times 
daily for 3 days) was started in the morning 5 days after 
they ingested the dose. None of the volunteers became ill 
enough to warrant earlier treatment.
Microbiological detection of ETEC
Stool specimens were acquired daily starting on the first 
day after the dose had been ingested. The specimens were 
streaked onto Enterobacteriaceae-selective Lactose Agar 
(Haukeland University Hospital, Bergen, Norway), fol-
lowed by over-night incubation at 35  °C. A sample was 
considered to be negative for ETEC if no E. coli-like col-
onies were seen on the plate. If colonies were present, a 
representative selection of colonies from the most conflu-
ent part of the plate was collected with a 1 µl inoculation 
loop, DNA was then extracted by boiling and centrifuga-
tion followed by testing the supernatant for the presence 
of the ETEC toxin genes by PCR as described earlier [13].
Stool DNA purification
For this study, we designed a DNA purification method 
that enables extracting genomic DNA equally well from 
all stool microbes and minimizing the amount of co-puri-
fied PCR inhibitors while allowing for purification in a 
microplate format. Up to one stool specimen for each day 
from each volunteer was included in the study, includ-
ing the day the volunteers ingested the dose. Stools were 
stored for up to 20 h at 4 °C before being mixed by stir-
ring and a representative selection was stored aliquoted 
at − 70 °C. After thawing, around 50 mg of the specimen 
was suspended in 200 µl Lysis Buffer (100 mM Tris–Cl, 
pH 9.0, 40 mM EDTA, 1% SDS, 1 µg/µl Proteinase K) fol-
lowed by incubation at 60 °C for 60 min with ~ 160 mg 1:1 
mix of acid-washed 0.1 mm and 0.5 mm Ø glass beads in 
a 2 ml deep-well microplate covered with an aluminum 
foil seal for cold storage (Thermo Fisher Scientific, 
Waltham, MA). After a 2 × 1 min vigorous vortex of the 
sealed plate, 70 µl 6 M ammonium acetate was added to 
each well, followed by re-sealing and mixing with a gentle 
vortex, 20 min incubation at − 20 °C to precipitate SDS, 
a 60  s vigorous vortex, and a 6000×g centrifugation for 
20 min at 4 °C in a Heraeus Multifuge X3 centrifuge fit-
ted with a HIGHPlate 6000 Microplate Rotor (Thermo 
Fisher Scientific, Waltham, MA). Note that the integrity 
of the aluminum foil seal should be checked before vor-
texing, and that a fresh foil should be added after add-
ing the ammonium acetate. Up to 200 µl of the resulting 
supernatant was incubated agitated in room temperature 
for 30  min in a Nunc 96-well Fritted Deep Well Plate 
(Thermo Fisher Scientific) that contained approximately 
90 µl powdered polyvinylpolypyrrolidone (110 µm parti-
cle size; Merck, Darmstadt, Germany), 50 mg Amberlite-
XAD4 (Merck), and 50  mg Dowex-1X8 (Merck) resins. 
Prior to adding the supernatants, the resin, which reduces 
the amounts of potential PCR inhibitors, had been indi-
vidually distributed to wells where they subsequently 
soaked for 2–3 h in 200 µl Equilibration Buffer (75 mM 
Tris–Cl, pH 9.0, 30  mM EDTA, and 1.5  M ammonium 
acetate) before buffer removal by centrifugation at 800×g 
for 1 min. After incubation, the filtrates were collected by 
centrifugation into a 1.2  ml low-profile microplate, and 
nucleic acids were precipitated by adding 200 µl isopro-
panol followed by 20 min agitation at room temperature 
and centrifugation at 6000×g for 20  min at 4  °C. After 
pipette aspiration, 50  µl Digest Buffer (20  mM Tris–Cl, 
pH 8.0, 4 mM EDTA, 0.8 µg/µl RNAse A, 1.6 µg/µl Pro-
teinase K, 20 mM TCEP, and 0.05% Tween-20) that had 
been prepared immediately before use was added while 
the DNA pellets were still wet, and the plate was incu-
bated agitated for 30 min at 37 °C. A mix of 20 µl AMPure 
XP (Beckman Coulter Inc., Brea, CA) and 70 µl Binding 
Buffer (10 mM Tris–Cl, pH 8.0, 1 mM EDTA, 20% PEG 
8000, 2.5  M NaCl, and 0.05% Tween-20) was added to 
each sample and mixed by pipetting, followed by trans-
fer to a 350 µl round-bottom polypropylene microplate, 
incubation for ≥ 10 min at room temperature, and incu-
bation on a microplate magnet for ≥ 5 min. After discard-
ing the supernatant, the magnetic beads were washed by 
re-suspending them in 90 µl Binding Buffer before wash-
ing twice with 70% ethanol on the magnet. After 2 min 
air drying, 50  µl Dilution Buffer (10  mM Tris–Cl, pH 
8.0, 0.05% Tween-20) was added to the beads, and, after 
30 min incubation with agitation at 37  °C, the superna-
tant containing the DNA was stored at − 20 °C.
qPCR oligonucleotides
A probe-based qPCR assay was developed for quan-
titating TW11681 bacteria. The qPCR primers were 
designed to target the E. coli O19-specific O-antigen 
polymerase gene (wzy, 1,179  bp; GenBank accession 
no.: LC223608.1), which is present as a single copy on 
the TW11681 chromosome. Gene sequences from 37 E. 
coli strains having > 90% sequence identity with wzy in 
TW11681, 35 of which had 100% identity, were down-
loaded from the whole-genome shotgun contigs data-
base in GenBank and included in the alignment. The 
gene appears to have little sequence similarities with 
other known prokaryote and eukaryote sequences. The 
forward (GAT GGT TAG TTT TAT GAC TGG; O19-wzy-
TF) and reverse (GAA GAG ACT AAG AAC TTA GTTG; 
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O19-wzy-TR) primers bind at gene nucleotide posi-
tions 941 and 1022, respectively, producing an 81  bp 
PCR fragment, and the probe (AGC ACT CTT CTC GAT 
TCC GACA; O19-wzy-TP), which binds at nucleotide 
993, was labelled with 6-FAM (5′-end) and BHQ1 (3′-
end). Primer3 [18] was used to test the suitability of the 
selected primer and probe sequences. The primers have 
100% identity with the genes used in the above-men-
tioned alignment, except the forward primer has one 
mismatch in position 5 against wzy of O19 E. coli strain 
FCP1.
qPCR assays
Immediately before running the qPCR assays, the puri-
fied stool DNA was quantified by using the QuantiF-
luor dsDNA System (Promega Corporation, Madison, 
WI) and diluted in Dilution Buffer to 1.0 and 0.1  ng/µl 
for use as template DNA in the qPCR assay. The assay 
was performed on four replicates, two for each template 
dilution, in white 384-well PCR plates on a LightCycler 
480 machine (Roche Life Science, Penzberg, Germany). 
Each 9  µl reaction contained 1X ABsolute qPCR mix 
(Thermo Fisher Scientific), 0.4 µg/µl each of O19-wzy-TF 
and O19-wzy-TR primers, 0.2 µg/µl O19-wzy-TP probe, 
and 1.5 µl template DNA. The plates were incubated for 
15 min at 95 °C, followed by 45 cycles of 20 s at 95 °C and 
90 s at 60 °C.
The positive control DNA template was prepared from 
frozen aliquots of purified genomic DNA from three 
strains (TW11681, ETEC strain TW10722 [O115:H5], 
and E. coli laboratory strain BL21(DE3) [O7:H-]) that 
had been diluted in Dilution Buffer and pooled to a final 
concentration of 0.5  ng/µl of each strain. Tenfold dilu-
tions ranging from 0.5  ng/µl to 50  fg/µl, as well as 25 
and 12.5  fg/µl were used in triplicates as template DNA 
for positive controls in the assay, while Dilution Buffer 
was used for the corresponding no template controls. 
Since each TW11681 genome is 5.30 Mbp and, there-
fore, weights 5.7 fg, 1.5 µl of the positive control template 
dilutions added to the qPCR ranges from 132,000 to 3 
TW11681 genome copies.
qPCR curves were analyzed by using the LightCy-
cler 480 Software, version 1.5.1.62 (Roche Life Science), 
where the quantitation cycle (Cq) for each curve was 
determined by using the Second Derivative Maximum 
Method. The regression curve of the results from the 
positive control dilution series was generated by using 
the same software, and the linear dynamic range of the 
assay was subsequently set to span the dilutions that 
gave Cq results that closely conformed to this regression 
curve.
We tested the suitability of the qPCR annealing and 
elongation temperature by running the assay on a 
temperature gradient spanning 50–63  °C. When sepa-
rated on a 4% agarose gel, a single distinct band corre-
sponding to the expected 81  bp PCR product was seen 
for all reactions (data not shown), suggesting that 60  °C 
is suitable for the assay. We chose to use a long (90  s) 
annealing and elongation time to allow for more flexibil-
ity if multiplexing the assay with primers for additional 
qPCR targets.
To check for any negative effects of PCR inhibitors in 
the sample template DNA, we assessed whether the reac-
tions containing 0.1 ng/µl template DNA tended to have 
higher PCR efficiencies than those containing 1.0  ng/
µl template DNA. We calculated the mean Cq differ-
ence between the two replicates that were based on the 
1.0  ng/µl template DNA and those that were based on 
the 0.1  ng/µl template DNA, excluding results that fell 
outside the estimated linear dynamic range of the assay. 
Histograms and Normal Q–Q Plots were then drawn to 
visually assess whether the distribution of these differ-
ences was normally distributed and symmetric, and Sha-
piro–Wilk Normality Test and Sample Skewness based 
on the traditional Fisher-Pearson Coefficient of Skewness 
test were performed to test these assumptions. We used 
the moments package [19] in R, version 3.4.2 [20] for 
these analyses.
Immunological assays
Serum was prepared from blood collected 0, 10, and 
28 days after the TW11681 cells had been ingested. We 
used multiplex flow-cytometry bead assays to measure 
IgA and IgG/IgM antibody responses to the two proteins 
CfaB (UniProtKB ID: P0CK93) and YghJ (UniProtKB ID: 
A0A080EY22). CfaB is the major structural protein of 
the plasmid-encoded fimbrial ETEC colonization fac-
tor CFA/I [5], while YghJ is a highly conserved enzyme 
involved in degrading the major mucins in the small 
intestine during ETEC colonization [21]. The genes 
encoding CfaB and YghJ, excluding the sequence encod-
ing the signal peptides, were amplified by PCR and 
cloned into the pET-30 (Merck Millipore, Burlington, 
MA) expression vector. The 16 and 167 kDa, respectively, 
proteins were expressed in ClearColi BL21(DE3) cells 
(Lucigen, Middleton, WI) and purified by His-tag cap-
ture and dialysis against 20 mM phosphate buffer, pH 7.4 
containing 0.3  M NaCl. The proteins were cross-linked 
to Cyto-Plex carboxylated polystyrene beads (Thermo 
Fisher Scientific) by using carboxyl-reactive chemis-
try, incubated with human volunteer serum and, subse-
quently, with fluorescently labeled anti-IgA or anti-IgG/
IgM secondary antibodies (Jackson ImmunoResearch 
Inc, West Grove, PA). Each bead’s secondary antibody 
fluorescence intensity was measured on a flow cytome-
ter, and the median intensity minus the median intensity 
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of the negative control, which was beads labeled with 
His-tag labeled glutatione s-transferase, was used in the 
analyses.
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